Activation of Nrf2 signaling as a common treatment of neurodegenerative diseases by Dinkova-Kostova, Albena T. & Kazantsev, Aleksey G.
                                                              
University of Dundee
Activation of Nrf2 signaling as a common treatment of neurodegenerative diseases









Link to publication in Discovery Research Portal
Citation for published version (APA):
Dinkova-Kostova, A. T., & Kazantsev, A. G. (2017). Activation of Nrf2 signaling as a common treatment of
neurodegenerative diseases. Neurodegenerative Disease Management, 7(2), 97-100.
https://doi.org/10.2217/nmt-2017-0011
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 05. Apr. 2019
Title: Activation of Nrf2 signaling as a common treatment of neurodegenerative diseases  
 
Albena T. Dinkova-Kostova1,2 and Aleksey G. Kazantsev3* 
 
 
1- Division of Cancer Research, School of Medicine, University of Dundee 
2- Departments of Medicine and Pharmacology and Molecular Sciences, Johns Hopkins   
      University School of Medicine 
3- Former: Department of Neurology, Massachusetts General   
      Hospital and Harvard Medical School; Current Effective Therapeutics 
 






The devastating age-dependent neurodegenerative disorders, including prevalent Alzheimer’s 
(AD) and Parkinson’s diseases (PD), as well as rare such as Huntington’s chorea (HD) and Amyotrophic 
Lateral Sclerosis (ALS), affect millions of people worldwide. Their prevalence is projected to increase 
due to ageing of the population, with a corresponding increase in the associated socioeconomic impact.  
Currently, there is no disease-modifying therapy for any neurodegenerative disease.  Symptomatic 
treatments are available for some conditions such as PD and HD, but the therapeutic benefits are transient 
and limited. Although the causative factors and clinical manifestations are distinct for each 
neurodegenerative disease, their molecular pathogeneses share common underlying factors, such as 
excessive levels of reactive oxygen species (ROS), largely due to mitochondrial impairment, 
neuroinflammation, and disturbances in protein homeostasis (proteostasis). This raises the exciting 
possibility for developing a universal treatment, targeting these common drivers of neurodegeneration.  
The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) orchestrates a major 
endogenous defense mechanism against oxidative and xenobiotic stress, and inflammation, and plays a 
role in the maintenance of mitochondrial function and cellular proteostasis, suggesting potential benefits 
of therapeutic targeting of Nrf2 to counteract neurodegeneration. Under stress condition(s), Nrf2 activates 
the transcriptional upregulation of a large network of cytoprotective genes, allowing adaptation and 
survival [1].  The levels (and activity) of Nrf2 are tightly regulated through ubiquitination and 
proteasomal degradation mediated by several ubiquitin ligase systems, including Kelch-like ECH-
associated protein 1 (Keap1)-Cullin3 (Cul3)/Rbx1, β-transducin repeats-containing protein (β-TrCP)-
Cul1, and synoviolin (Hrd1) [2]. Of these, Keap1 is the best-understood key negative regulator of Nrf2.   
Keap1 serves as a sensor for electrophiles and oxidants, which chemically modify specific cysteines in 
Keap1, resulting in conformational changes that protect Nrf2 from Keap1-directed degradation. As a 
result, Nrf2 accumulates, translocates to the nucleus, binds (as a heterodimer with a small Maf 
transcription factor) to antioxidant response elements (AREs) in the promoter of its target genes, and 
activates the expression of a large network of detoxification, antioxidant, and anti-inflammatory genes as 
well as genes involved in clearance of damaged proteins [1]. Of particular interest is upregulation of 
genes responsible in biosynthesis and regeneration of glutathione (GSH), a major intracellular 
antioxidant. Nrf2 also suppresses pro-inflammatory responses, in part through transcriptional repression 
[3], and is involved in the maintenance of mitochondrial function [4]. Keap1 and autophagosome cargo 
sequestosome-1 protein (p62/SQSTM1) are Nrf2-responisve proteins and principal regulators of negative 
and positive feedback loop mechanisms respectively. Additionally, p62 targets Keap1 for selective 
degradation through autophagy [5], thus contributing to sustained Nrf2 activation response.  
Ageing is associated with increases in ROS and chronic inflammation, suggesting a loss of 
adaptability and/or impairment of Nrf2 signaling, which are particularly pronounced in age-dependent 
neurodegenerative diseases [6]. Intriguingly, rare mutations in SQSTM1 cause susceptibility to the human 
neurodegenerative condition ALS and frontotemporal lobar degeneration (FTLD), and are associated with 
muted Nrf2 activation responses in disease models [7]. Studies suggest a reciprocal relationship and show 
negative influence of mutant disease-causative proteins on Nrf2 signaling, thereby implicating inhibition 
of the Nrf2 pathway as a possible mechanism underlying severity and progression of neurodegeneration.   
ALS, an adult-onset neurodegenerative disease caused by selective death of motor neurons (MNs) in the 
brain and spinal cord, is characterized by progressive muscle weakness and atrophy and is uniformly 
fatal, usually within five years of clinical presentation [8, 9]. ALS has a predominant sporadic (sALS) 
form with no apparent genetic component, however approximately 5-10% clinical cases display an 
autosomal dominant inheritance pattern or familial form of disease (fALS) with known gene causative 
mutations. The clinical features of sALS and fALS are remarkably similar, suggesting involvement of 
common pathogenic mechanisms like oxidative stress and neuroinflammation. 
Collective work elucidated the oxidative stress and neuroinflammation as the key therapeutic 
targets of Nrf2 signaling in ALS [10]. Genetic studies in ALS mouse models have shown a significant 
therapeutic effect of elevated Nrf2 levels in astrocytes, the major GSH suppliers for neighboring neurons. 
Moreover, Nrf2 signaling is critical for attenuating neuroinflammation in ALS through repression of the 
deleterious effects of activated microglia on neuronal survival. Consistent with the therapeutic potential of 
Nrf2 signaling, treatment with small molecule activators, including the extremely potent cyanoenone 
triterpenoids, have shown efficacy in mouse ALS models [11].   
The neuroprotective potential of Nrf2 activation has been evaluated in experiments using genetic 
mouse HD models. HD is an autosomal dominant and highly penetrant neurodegenerative disorder, which 
results from the pathological expansion of a trinucleotide CAG repeats encoding polyglutamines in 
huntingtin (HTT) protein [12]. Brains from HD patients typically display marked striatal and cortical 
atrophy at the time of diagnosis. Once motor or other symptoms become apparent, typically during mid-
life, the affected individuals become increasingly disabled over the course of 15-25 years before 
succumbing to the effects of severe physical and mental deterioration.  
Complex pathogenic mechanisms have been implicated in HD, however excessive oxidative 
stress has been recognized as an important driver of pathology [13]. The harmful role of oxidative stress 
has been described in both HD patients and in experimental models, and is potentially due to inherent 
neuronal sensitivity to an excess of ROS. The levels of several Nrf2-dependent antioxidant proteins, 
including glutathione peroxidases, catalase, and SOD, are increased in human HD brains compared to 
non-disease controls, suggesting a partial activation of Nrf2 defense signaling, yet insufficient to block 
progressive neurodegeneration.  Consistent with that notion, pharmacological activation of Nrf2 induces 
broad antioxidant effects in HD mouse brain and ameliorate the neurological phenotype [10]. Elevated 
expression of several key inflammatory mediators has been observed in blood, striatum, cortex, and 
cerebellum from post-mortem patient HD tissues, yet neuroinflammation in HD appears to be less 
pronounced than in ALS or PD. 
 Similarly, the neurological phenotype of the more prevalent neurodegenerative disease, PD, can 
be ameliorated by Nrf2 activation [14]. PD is characterized by progressive loss of dopaminergic neurons 
in the substantia nigra and profound reduction of dopamine in the striatum. Currently available 
dopaminergic treatments offer partial symptomatic relief and only address the motor manifestations. 
Multiple genetic and environmental factors have been implicated in PD etiology, however, similar to 
ALS, the majority of the clinical cases are sporadic. The discovery, that the environmental neurotoxin 1-
methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) causes Parkinsonism in humans, led to the 
development of the MPTP mouse model of disease, which to date remains a highly utilized animal model 
of sporadic PD, including evaluation of drug efficacy [15]. Nrf2 activators showed neuroprotective effects 
in MPTP mice, which are associated with a reduction of oxidative damage and neuroinflammation [15]. 
The identification of causative mutations in SNCA, the gene encoding alpha-synuclein (aSyn), paved the 
way for developing genetic mouse PD models, in which daily oral delivery of the Nrf2 activator dimethyl 
fumarate (DMF) protected nigral dopaminergic neurons against α-SYN toxicity [16].  
Although oxidative stress and neuroinflammation constitute pathological hallmarks of AD, a 
therapeutic role of Nrf2 signaling has emerged more slowly, perhaps due to the complexity of disease 
pathogenesis and readouts of efficacy. Nevertheless there is a number of recent publications which 
demonstrate the efficacy of Nrf2 activators in AD mouse models [17].  
DMF, an FDA-approved drug (Tecfidera, Biogen-Idec) for the treatment of relapsing multiple 
sclerosis (MS) [18], activates Nrf2 through covalent modification of the Keap1 sensor. DMF is of 
relatively low potency and specificity, which prevents its broad repurposing for neurodegenerative 
indications. Drug-like molecules with similar mechanism of action or with ability of direct interference 
with the Keap1/Nrf2 interaction are emerging [19, 20]. Most excitingly, the available data demonstrate 
the feasibility to develop Nrf2 activators for clinical use as a unified strategy for the prevention and 
treatment of a broad range of currently incurable neurodegenerative diseases.   
In summary, although the clinical manifestations of neurodegenerative diseases are distinct, these 
disorders share similar molecular mechanisms of neurodegeneration, which could be counteracted by 
common treatment with Nrf2 activators. Moreover, targeting Nrf2 signaling may provide an exciting 
therapeutic option to ameliorate disease pathology in majority of clinical cases with unknown etiology. 
Because pharmacological Nrf2 activation targets broad mechanisms of disease, all neurodegenerative 
conditions would be eligible for therapy. Therefore a major goal is to develop non-invasive oral 
treatment(s) for outpatient settings under supervision of primary care physicians, which targets both 
sporadic and familial patients. With simple and inexpensive drug synthesis and manufacturing and a 
straightforward treatment regimen, the medical cost is expected to be low, with meaningful impact on 
disease burden and survival. It is also expected that Nrf2 activating drugs would be self-administered, 
avoiding additional clinical visits, except those incurred from a longer life expectancy. For clinicians, it 
would revolutionize the approach to therapy and provide a meaningful treatment option where few have 
ever existed and entire practices would be reworked to ensure that all patients are offered therapy 
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